(Q41814914)

English

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

scientific article published on 25 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium (English)

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

phase II clinical trial

0 references

Kathleen A. Cooney

5

object named as

Kathleen A Cooney

0 references

Kenneth J. Pienta

12

object named as

Kenneth J Pienta

0 references

object named as

Mitchell E Gross

9

0 references

object named as

David C Smith

6

0 references

Stephanie Daignault

2

object named as

Stephanie Daignault

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Deborah A Bradley

1

object named as

Deborah A Bradley

1 reference

Europe PubMed Central

12 October 2017

PMC publication ID

16

object named as

Evan T Keller

1 reference

Europe PubMed Central

12 October 2017

PMC publication ID

June Escara-Wilke

13

object named as

June Escara-Wilke

1 reference

Europe PubMed Central

12 October 2017

PMC publication ID

7

object named as

Eric Small

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

author name string

Charles J Ryan

3

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Robert S Dipaola

4

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Paul Mathew

8

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Mark N Stein

10

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Alice Chen

11

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Gerald Doyle

14

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Mahmoud Al-Hawary

15

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Maha Hussain

17

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

publication date

25 March 2010

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

29

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

6

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

1432-1440

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9420-8

0 references

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Dynamic process of prostate cancer metastasis to bone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Emerging views of integrin signaling: implications for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Role of integrins in cell invasion and migration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Integrins and prostate cancer metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

The role of alpha(v)beta(3) in prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Multiple roles of integrins in cell motility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Integrins and signaling in osteoclast function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Integrin function in osteoclasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Role of integrins and other cell adhesion molecules in tumor progression and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Anchorage dependence, integrins, and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

6 June 2018

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Downregulation of the beta4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917503

18 August 2018

Co-ordinated changes in expression of cell adhesion molecules in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9420-8

21 January 2018

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9420-8

21 January 2018

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating tumor cells predict survival in patients with metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrin expression in human bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9420-8

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Dimensions Publication ID

0 references

release_7ylc6mlyxngkxa4q7uwarccxj4

1 reference

https://api.fatcat.wiki/v0/release/7ylc6mlyxngkxa4q7uwarccxj4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41814914&oldid=2186406461"